Method of inhibiting or treating cancer metastasis

Abstract

The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90α having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.

The invention claimed is: 
     
       1. A method of inhibiting or treating cancer metastasis in a subject in need thereof, which comprises administering an inhibitor of a polypeptide consisting of SEQ ID NO:1 to said subject, wherein said inhibitor is a specific antibody against said polypeptide consisting of SEQ ID NO:1, wherein said antibody is MAb E9 produced by the cell line deposited under CGMCC No. 2903 or MAb D10 produced by the cell line deposited under CGMCC No. 2904. 
     
     
       2. The method of  claim 1 , wherein said cancer is selected from the group consisting of lung cancer, liver cancer, pancreatic cancer, breast cancer, and cervical carcinoma. 
     
     
       3. The method of  claim 1 , wherein said subject has a plasma level consisting of SEQ ID NO:1 of above 200 ng/mL. 
     
     
       4. A method of inhibiting or treating cancer metastasis in a subject with a plasma level of SEQ ID NO:1 that is above 200 ng/mL, comprising:
 i) detecting a level of the polypeptide consisting of SEQ ID NO:1 in a plasma sample of said subject using an antibody to determine if the patient has a plasma level of SEQ ID NO:1 above 200 ng/mL; and 
 ii) administering a specific antibody against said polypeptide consisting of SEQ ID NO:1 to said subject having a plasma level of SEQ ID NO:1 of above 200 ng/mL, wherein said specific antibody is MAb E9 produced by a cell line deposited under CGMCC No. 2903 or MAb D10 produced by a cell line deposited under CGMCC No. 2904. 
 
     
     
       5. The method of  claim 4 , wherein said cancer metastasis is from a cancer selected from the group consisting of lung cancer, liver cancer, pancreatic cancer, breast cancer, and cervical carcinoma.